Nov 8, 2024, 2:10 PM
Nov 8, 2024, 2:10 PM
New Civil Liberties Alliance Challenges HHS's Drug Price Policy
- The New Civil Liberties Alliance filed a brief against the Department of Health & Human Services in a recent legal case.
- The brief argues that the Medicare drug price negotiation program infringes upon constitutional property rights.
- NCLA's actions highlight concerns over government overreach and potential impacts on both large pharmaceutical companies and small businesses.
On November 8, 2024, the New Civil Liberties Alliance (NCLA) submitted an amicus curiae brief to the U.S. Court of Appeals for the Second Circuit, opposing the Department of Health & Human Services' (HHS) Medicare drug price negotiation program. The NCLA claims that this program unlawfully coerces pharmaceutical companies to surrender their constitutional property rights, violating the unconstitutional conditions doctrine. The Inflation Reduction Act of 2022, aimed at lowering Medicare drug costs, is at the heart of this legal dispute.
Opinions
You've reached the end